Navigation Links
Respiratory Update: Interpreting Minimal Clinically Important Differences in COPD and Demonstrating Product Value with PROs, a New Life Science webinar Hosted by Xtalks
Date:11/25/2013

Toronto, Canada (PRWEB) November 25, 2013

Pharmaceutical companies face the daunting task of getting new respiratory products approved and launched in a crowded marketplace. Two main challenges in respiratory clinical trials are; interpreting minimal clinically important differences (MCID) and designing a patient reported instrument to demonstrate a compound’s value. Both are critical in the approval of your compound as well as in post marketing activities.

To compete effectively in the respiratory market, it is critical to show the value of your product over the competition. One way to do this is to examine the effect of new products on patients using Patient Reported Outcomes (PROs).

Join esteemed speakers Dr. Chad Gwaltney, Senior Director of Consulting Services at ERT, and Dr. Kai-Michael Beeh, Founder and Medical Director at insaf Respiratory Research Institute, as they examine MCIDs and different types of PROs that are available for respiratory diseases and review case studies of successful demonstrations of product value in respiratory programs.

For more information on this webinar or to register, visit: http://xtalks.com/Respiratory-Update-COPD-Product-value-and-PROs.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11363239.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Anesthesia and Respiratory Devices Market is Expected to Reach USD 21.6 Billion Globally in 2019: Transparency Market Research
2. Europe Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Southeast Asia Drug and Medical Device Update: Market Potential and Regulatory Environment, New Life Science Webinar Hosted by Xtalks
5. Patent Bar Exam Update: New Information Tested and More Changes to Come
6. Research update: Chips with self-assembling rectangles
7. QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments
8. Minimally Invasive Devices Adds $2.5 Million to its Series B
9. US Minimally Invasive Spine Technology Market to Grow Strongly to $2 Billion by 2017
10. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
11. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):